American International Group Inc. raised its stake in Fluidigm Corporation (NASDAQ:FLDM) by 7.1% during the first quarter, Holdings Channel reports. The institutional investor owned 17,907 shares of the medical research company’s stock after buying an additional 1,187 shares during the period. American International Group Inc.’s holdings in Fluidigm Corporation were worth $102,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC acquired a new position in shares of Fluidigm Corporation during the fourth quarter valued at approximately $1,165,000. Metropolitan Life Insurance Co. NY increased its position in shares of Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock valued at $151,000 after buying an additional 632 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Fluidigm Corporation during the fourth quarter valued at approximately $119,000. Norges Bank acquired a new position in shares of Fluidigm Corporation during the fourth quarter valued at approximately $1,196,000. Finally, Acadian Asset Management LLC increased its position in shares of Fluidigm Corporation by 46.0% in the first quarter. Acadian Asset Management LLC now owns 301,705 shares of the medical research company’s stock valued at $1,716,000 after buying an additional 95,056 shares in the last quarter. Institutional investors own 91.66% of the company’s stock.

Shares of Fluidigm Corporation (FLDM) traded down 0.2988% on Friday, hitting $3.3699. The stock had a trading volume of 17,895 shares. The company’s market capitalization is $99.12 million. The company has a 50-day moving average of $3.76 and a 200 day moving average of $4.97. Fluidigm Corporation has a 52 week low of $2.52 and a 52 week high of $9.65.

Fluidigm Corporation (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $23.50 million. During the same period last year, the company earned ($0.63) earnings per share. The business’s revenue for the quarter was down 15.2% on a year-over-year basis. On average, equities research analysts predict that Fluidigm Corporation will post ($2.19) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Fluidigm Corporation (FLDM) Shares Bought by American International Group Inc.” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/fluidigm-corporation-fldm-shares-bought-by-american-international-group-inc/1475071.html.

FLDM has been the subject of several research analyst reports. Zacks Investment Research downgraded Fluidigm Corporation from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

In related news, insider Steven Mcphail purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was purchased at an average cost of $3.00 per share, with a total value of $60,000.00. Following the completion of the acquisition, the insider now directly owns 27,842 shares of the company’s stock, valued at $83,526. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen Christopher Linthwaite purchased 45,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was bought at an average cost of $2.66 per share, with a total value of $119,700.00. Following the completion of the acquisition, the chief executive officer now directly owns 106,977 shares of the company’s stock, valued at $284,558.82. The disclosure for this purchase can be found here. Insiders bought 100,895 shares of company stock valued at $279,129 over the last ninety days. Corporate insiders own 4.70% of the company’s stock.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Corporation (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.